2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States

Katherine A Poehling, Herve Caspard, Timothy R Peters, Edward A Belongia, Blaise Congeni, Manjusha Gaglani, Marie R Griffin, Stephanie A Irving, Poornima K Kavathekar, Huong Q McLean, Allison L Naleway, Kathleen Ryan, H Keipp Talbot, Christopher S Ambrose, Katherine A Poehling, Herve Caspard, Timothy R Peters, Edward A Belongia, Blaise Congeni, Manjusha Gaglani, Marie R Griffin, Stephanie A Irving, Poornima K Kavathekar, Huong Q McLean, Allison L Naleway, Kathleen Ryan, H Keipp Talbot, Christopher S Ambrose

Abstract

Background: In the 2015-2016 season, quadrivalent live attenuated influenza vaccine (LAIV) and both trivalent and quadrivalent inactivated influenza vaccine (IIV) were available in the United States.

Methods: This study, conducted according to a test-negative case-control design, enrolled children aged 2-17 years presenting to outpatient settings with fever and respiratory symptoms for <5 days at 8 sites across the United States between 30 November 2015 and 15 April 2016. A nasal swab was obtained for reverse-transcriptase polymerase chain reaction (RT-PCR) testing for influenza, and influenza vaccination was verified in the medical record or vaccine registry. Influenza vaccine effectiveness (VE) was estimated using a logistic regression model.

Results: Of 1012 children retained for analysis, most children (59%) were unvaccinated, 10% received LAIV, and 31% received IIV. Influenza A (predominantly antigenically similar to the A/California/7/2009 strain) was detected in 14% and influenza B (predominantly a B/Victoria lineage) in 10%. For all influenza, VE was 46% (95% confidence interval [CI], 7%-69%) for LAIV and 65% (48%-76%) for IIV. VE against influenza A(H1N1)pdm09 was 50% (95% CI, -2% to 75%) for LAIV and 71% (51%-82%) for IIV. The odds ratio for vaccine failure with RT-PCR-confirmed A(H1N1)pdm09 was 1.71 (95% CI, 0.78-3.73) in LAIV versus IIV recipients.

Conclusions: LAIV and IIV demonstrated effectiveness against any influenza among children aged 2-17 years in 2015-2016. When compared to all unvaccinated children, VE against influenza A(H1N1)pdm09 was significant for IIV but not LAIV.

Clinical trials registration: NCT01997450.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Distribution of influenza cases and controls by week of enrollment.
Figure 2.
Figure 2.
Box-and-whisker plots of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) vaccine effectiveness (VE) against any influenza strain in the primary population (A) and after exclusion of partially vaccinated children (B), children testing negative for any respiratory virus (C), children presenting with high-risk medical conditions (D), or children enrolled at sites that enrolled <30 children (Florida, Minnesota, Ohio, and Oregon) (E). Abbreviation: CI, confidence interval.

References

    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. . The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086–96.
    1. Fowlkes A, Steffens A, Temte J et al. ; Influenza Incidence Surveillance Project Working Group. Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. Lancet Respir Med 2015; 3:709–18.
    1. Schanzer D, Vachon J, Pelletier L. Age-specific differences in influenza A epidemic curves: do children drive the spread of influenza epidemics?Am J Epidemiol 2011; 174:109–17.
    1. Peters TR, Snively BM, Suerken CK, Blakeney E, Vannoy L, Poehling KA. Relative timing of influenza disease by age group. Vaccine 2014; 32:6451–6.
    1. Fiore AE, Shay DK, Broder K et al. ; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1–60.
    1. Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States. Vaccine 2016; 34:61–6.
    1. Davis MM, King JC Jr, Moag L, Cummings G, Magder LS. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008; 122:e260–5.
    1. Loeb M, Russell ML, Manning V et al. . Live attenuated versus inactivated influenza vaccine in Hutterite children: a cluster randomized blinded trial. Ann Intern Med 2016; 165:617–24.
    1. Caspard H, Gaglani M, Clipper L et al. . Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. Vaccine 2016; 34:77–82.
    1. McLean HQ, Caspard H, Griffin MR et al. . Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine 2017; 35:2685–93.
    1. Ashkenazi S, Vertruyen A, Arístegui J et al. ; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870–9.
    1. Belshe RB, Edwards KM, Vesikari T et al. ; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685–96.
    1. Fleming DM, Crovari P, Wahn U et al. ; CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents. Pediatr Infect Dis J 2006; 25:860–9.
    1. Chung JR, Flannery B, Thompson MG et al. . Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016; 137:e20153279.
    1. Gaglani M, Pruszynski J, Murthy K et al. . Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis 2016; 213:1546–56.
    1. Davlin SL, Blanton L, Kniss K et al. . Influenza Activity—United States, 2015-16 season and composition of the 2016-17 influenza vaccine. MMWR Morb Mortal Wkly Rep 2016; 65:567–75.
    1. Jackson ML, Chung JR, Jackson LA et al. . Influenza vaccine effectiveness in the United States—2015/16 season. N Engl J Med 2017; 377:534–43.
    1. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep 2015; 64:818–25.
    1. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165–8.
    1. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104–9.
    1. Griffin MR, Monto AS, Belongia EA et al. ; U.S. Flu-VE Network. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6:e23085.
    1. Uzicanin A, Thompson M, Smith P et al. . Effectiveness of 1 dose of influenza A(H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 inflection among school-aged children in Maine. J Infect Dis 2012; 206:1059–68.
    1. Eick-Cost AA, Tastad KJ, Guerrero AC et al. . Effectiveness of seasonal influenza vaccines against influenza-associated illnesses among US military personnel in 2010-11: a case-control approach. PLoS One 2012; 7:e41435.
    1. Caspard H, Coelingh KL, Mallory RM, Ambrose CS. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. Vaccine 2016; 34:5066–72.
    1. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds—a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill 2016; 21:30346.
    1. Skowronski D. Live attenuated influenza vaccine (LAIV) vs. inactivated influenza vaccine (IIV): summary of effectiveness evidence since 2009 In: Program and abstracts of the National Advisory Committee on Immunization, Influenza Working Group, Ottawa, Ontario: (Updated 2016.) Available at: . Accessed 28 March 2017.
    1. Helmeke C. Effektivität der influenza-impfstoffe bei kindern in Sachsen-Anhalt und Niedersachsen 2015/16 Available at: . Accessed 6 February 2017.
    1. Pebody R, Warburton F, Ellis J et al. . Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill 2016; 21:30348.
    1. Flannery B, Chung J. Influenza vaccine effectiveness, including LAIV vs IIV in children and adolescents, US Flu VE Network, 2015-16 Presented at the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Meeting, 22–23 June 2016, Atlanta, GA: Available at: . Accessed 6 February 2017.
    1. Grohskopf LA, Sokolow LZ, Broder KR et al. . Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2016; 65:1–54.
    1. Pebody R, Sile B, Warburton F et al. . Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Euro Surveill 2017; 22:pii: 30450
    1. National Services Scotland. Flu vaccine effectiveness in Scottish primary school age children from the 2015/2016 season Available at: . Accessed 6 February 2017.
    1. Broberg E, Melidou A, Prosenc K, Bragstad K, Hungnes O, on behalf of the WHO European Region and the European Influenza Surveillance Network members of the reporting countries: predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. Euro Surveill 2016; 21:pii=30184.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir